Analytical Data
-
基因名
MCP-1/CCL2
-
简介
MCP-1/CCL2 protein activates CCR2 and induces chemotaxis and calcium ion mobilization. It attracts monocytes and basophils, not neutrophils or eosinophils. It also contributes to neuropathic pain and enhances synaptic transmission in dopamine neurons. MCP-1/CCL2 exists as a monomer or homodimer and binds to endothelial cells through proteoglycans. It interacts with TNFAIP6 via its Link domain. MCP-1/CCL2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived MCP-1/CCL2 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
别名
C-C motif chemokine 2; CCL2; HC11; MCAF; MCP-1; HSMCR30; MCP1; SCYA2; SMC-CF; GDCF-2
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P61274
-
表达区间
Q24-P99
-
蛋白长度
Full Length of Mature Protein
-
分子量
13-16 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MCP-1, also known as CCL2 (C-C motif chemokine ligand 2), is a crucial chemokine involved in the inflammatory response and plays a significant role in recruiting monocytes to sites of injury and inflammation. Its importance is underscored in various pathological conditions, including cardiovascular diseases, neurodegenerative disorders, and cancers, where MCP-1/CCL2 mediates immune responses and contributes to disease progression. The therapeutic potential of targeting MCP-1/CCL2 has led to extensive research aimed at understanding its functions and mechanisms. Recombinant MCP-1/CCL2 proteins are essential tools for dissecting these biological pathways, enabling researchers to explore their roles in cell signaling and interaction within the immune system. Studies have shown that modulation of MCP-1/CCL2 levels can alter inflammatory responses, suggesting that it may serve as a biomarker for disease progression and a target for therapeutic intervention. Furthermore, the generation of recombinant MCP-1/CCL2 proteins facilitates advanced investigations into its structure-function relationship, signaling cascades, and interactions with its receptors, which can lead to the development of novel therapeutic strategies. Overall, research on MCP-1/CCL2 recombinant proteins is critical for understanding their implications in health and disease, thereby opening avenues for potential clinical applications in inflammatory and autoimmune diseases.
